Based on the Cipla Limited stock forecast from 5 analysts, the average analyst target price for Cipla Limited is INR 1,447.20 over the next 12 months. Cipla Limited’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Cipla Limited is Bullish , which is based on 7 positive signals and 2 negative signals. At the last closing, Cipla Limited’s stock price was INR 1,398.20. Cipla Limited’s stock price has changed by +1.67% over the past week, -5.61% over the past month and +53.71% over the last year.
No recent analyst target price found for Cipla Limited
No recent average analyst rating found for Cipla Limited
Company Overview Cipla Limited
Cipla Limited, together with its subsidiaries, manufactures, develops, and sells pharmaceutical products in India, the United States, South Africa, and internationally. The company operates through Pharmaceuticals and New ventures segments. It also offers active pharmaceutical ingredients; and formulations in various therapeutic areas, such as MI, angina, heart failure, hypertension, arrhythmia, lipid abnormalities and diabetes, obesity, HIV, respiratory, urology, oncology, cardio-metabolism, child health, infectious diseases and critical care, hepatitis, women's health, ophthalmology, and neuro psychiatry. In addition, the company provides respiratory products, including inhalers and nasal sprays, as well as other respiratory products consists of injectables and biosimilars. Further, it offers Easylax and Easylax L, a liquid paraffin for constipation. Cipla Limited was incorporated in 1935 and is based in Mumbai, India. Address: Cipla House, Mumbai, India, 400013 Read Less
Cipla Limited, together with its subsidiaries, manufactures, develops, and sells pharmaceutical products in India, the United States, South Africa, and internationally. The company operates through Pharmaceuticals and New ventures segments. It also offers active pharmaceutical in...Read More
Frequently Asked Questions About Cipla Limited (CIPLA:NSE) Stock
Based on ratings from 5 analysts Cipla Limited's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bullish . The stock has 5 buy, sell and hold ratings.
CIPLA:NSE stock's dividend yield is 0.63%.
Our analysis grades CIPLA:NSE stock's dividend yield at F. This means that CIPLA:NSE stock's dividend yield is above 40% of the stocks in the Drug Manufacturers - General sector in the NSE exchange.
Based on this CIPLA:NSE may be a average dividend stock for its sector.
Based on targets from 5 analysts, the average taret price for CIPLA:NSE is INR 1,447.20 over the next 12 months. The maximum analyst target price is INR 1576 while the minimum anlayst target price is INR 1350.
CIPLA:NSE stock's Price/Earning ratio is 30.07.
Our analysis grades CIPLA:NSE stock's Price / Earning ratio at A-. This means that CIPLA:NSE stock's Price/Earning ratio is above 8.999999999999996% of the stocks in the Drug Manufacturers - General sector in the NSE exchange.
Based on this CIPLA:NSE may be undervalued for its sector.
The last closing price of CIPLA:NSE's stock was INR 1,398.20.
The most recent market capitalization for CIPLA:NSE is INR 1,121.02B.
Based on targets from 5 analysts, the average taret price for CIPLA:NSE is projected at INR 1,447.20 over the next 12 months.
This means that CIPLA:NSE's stock price may go up by +3.50% over the next 12 months.
Following are ETFs with the highest allocation to Cipla Limited's stock :
As per our most recent records Cipla Limited has 32,323 Employees.
Cipla Limited's registered address is Cipla House, Mumbai, India, 400013.
You can get more information about it from Cipla Limited's website at https://www.cipla.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Underpriced on cashflow basis
The stock is trading low compared to its peers on a price to cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Underpriced compared to earnings
The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Superior Dividend Growth
This stock has shown top quartile dividend growth in the previous 5 years compared to its sector
What not to like
Below median total returns
The company has under performed its peers on annual average total returns in the past 5 years.
Poor return on equity
The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for CIPLA:NSE !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
Stocktwits
